We are live on ! Find out more
CSTL icon

Castle Biosciences
CSTL

67 hedge funds and large institutions have $176M invested in Castle Biosciences in 2019 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 28 increasing their positions, 12 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

188% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 8

133% more repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 12

99% more capital invested

Capital invested by funds: $88.1M → $176M (+$87.5M)

18% more funds holding

Funds holding: 57 → 67 (+10)

1.4% more ownership

Funds ownership: 28.52% → 29.93% (+1.4%)

Holders
67
Holders Change
+10
Holders Change %
+17.54%
% of All Funds
1.32%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
23
Increased
28
Reduced
12
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$5.58M
2
PCM
Portolan Capital Management
Massachusetts
+$4.42M
3
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
+$4.36M
4
WA
Wasatch Advisors
Utah
+$2.47M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$2.14M

Top Sellers

Rank Fund Capital Flow
1
NAM
Nexpoint Asset Management
Texas
-$7.92M
2
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$4.07M
3
Millennium Management
Millennium Management
New York
-$2.81M
4
RI
RTW Investments
New York
-$2.79M
5
PVI
Pura Vida Investments
New York
-$2.38M
Name Holding Trade Value Shares
Change 		Change in
Stake
NAM
1
Nexpoint Asset Management
Texas
$24.3M -$7.92M -323,963 -31%
RI
2
RTW Investments
New York
$21.7M -$2.79M -113,973 -15%
BlackRock
3
BlackRock
New York
$15M +$5.58M +228,228 +110%
WA
4
Wasatch Advisors
Utah
$12.9M +$2.47M +100,856 +37%
DCM
5
Driehaus Capital Management
Illinois
$12.6M +$2.08M +85,231 +30%
PCM
6
Portolan Capital Management
Massachusetts
$10.5M +$4.42M +180,647 +145%
Goldman Sachs
7
Goldman Sachs
New York
$10.5M +$60.3K +2,467 +0.8%
AIM
8
ARK Investment Management
Florida
$7.08M +$976K +39,927 +24%
Vanguard Group
9
Vanguard Group
Pennsylvania
$6.89M +$2.14M +87,589 +78%
Lord, Abbett & Co
10
Lord, Abbett & Co
New Jersey
$6.13M +$4.36M +178,196 New
Federated Hermes
11
Federated Hermes
Pennsylvania
$4.8M +$1.83M +74,747 +115%
N
12
Nuveen
North Carolina
$3.94M -$1.24M -50,569 -31%
Calamos Advisors
13
Calamos Advisors
Illinois
$3.52M +$1.73M +70,845 +224%
ACH
14
ArrowMark Colorado Holdings
Colorado
$2.7M +$212K +8,655 +12%
EI
15
EAM Investors
California
$2.25M +$768K +31,407 +92%
Geode Capital Management
16
Geode Capital Management
Massachusetts
$2.02M +$509K +20,804 +55%
Northern Trust
17
Northern Trust
Illinois
$1.94M +$129K +5,287 +10%
EIM
18
Essex Investment Management
Massachusetts
$1.86M +$23.1K +945 +2%
Russell Investments Group
19
Russell Investments Group
United Kingdom
$1.84M +$888K +36,305 +210%
GIM
20
Granahan Investment Management
Massachusetts
$1.82M +$1.29M +52,863 New
OAM
21
Oberweis Asset Management
Illinois
$1.76M +$1.25M +51,200 New
State Street
22
State Street
Massachusetts
$1.76M +$369K +15,091 +42%
ZP
23
Zimmer Partners
New York
$1.75M – – –
EGI
24
EAM Global Investors
California
$1.7M +$132K +5,383 +12%
Squarepoint
25
Squarepoint
New York
$1.67M +$1.19M +48,690 New
1
2 3

CSTL Hedge Fund Activity: Q4 2019 in Review

67 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Castle Biosciences (CSTL) for Q4 2019, worth a combined $176M — up 99% from $88.1M a quarter earlier.

Buyers outnumbered sellers: 23 funds opened new CSTL positions and 8 closed out — a net gain of 15 holders — while 28 added to existing stakes and 12 trimmed.

The largest buyer was BlackRock, adding an estimated $5.58M. The largest seller was Nexpoint Asset Management, cutting an estimated $7.92M.

  • 67 institutional investors held Castle Biosciences (CSTL) as of Q4 2019, up from 57 in Q3 2019.
  • Funds reported $176M of Castle Biosciences stock for Q4 2019, up 99% quarter-over-quarter.
  • 23 funds opened new Castle Biosciences positions in Q4 2019 and 8 closed out, a net change of +15 holders.
  • The largest Castle Biosciences buyer in Q4 2019 was BlackRock, an estimated $5.58M added.
  • The largest Castle Biosciences seller in Q4 2019 was Nexpoint Asset Management, an estimated $7.92M sold.

Based on aggregated 13F filings for Q4 2019.